A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.
Ian Flinn, MD, PhD, Sarah Cannon Research Institute
Advertisement
Articles by Ian Flinn, MD, PhD, Sarah Cannon Research Institute
Advertisement
Latest Updated Articles
R2 Regimen for R/R Follicular LymphomaPublished: March 15th 2021 | Updated:
Role of Rebiopsy in R/R Follicular LymphomaPublished: March 1st 2021 | Updated:
Treating R/R DLBCL With CAR-T: Current BarriersPublished: February 26th 2021 | Updated:
Tazemetostat for R/R Follicular LymphomaPublished: March 22nd 2021 | Updated:
CAR T-Cell Therapy for R/R DLBCLPublished: February 19th 2021 | Updated:
R/R DLBCL: Transplants in the Era of CAR-TPublished: March 12th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5